NEW YORK, Nov. 8 – GPC Biotech of Munich said Thursday it had agreed to build a $120 million genomics research center for German chemicals and pharmaceuticals company Altana, which will use the new facility to advance two of its drug discovery programs.

Under the terms of the three agreements that make up the five-and-a-half-year deal, Altana has committed $120 million to the center, which it will own, over the duration of the alliance. The new center will be based in Waltham, Mass.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.